 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...179180181182183184185186187188189...235236» |
- | New P1/2 trial, Metastases: mFLOT Chemotherapy as First-line Treatment in GC (clinicaltrials.gov) - Jul 31, 2018
P1/2, N=56, Recruiting, Sponsor: Ruijin Hospital
- | cannabidiol (BRCX014) / Diverse Biotech
New P1/2 trial: A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies (clinicaltrials.gov) - Jul 31, 2018
P1/2, N=160, Not yet recruiting, Sponsor: Leaf Vertical Inc.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: Organ Preservation in Early Rectal Cancer Patients (clinicaltrials.gov) - Jul 30, 2018
P2, N=19, Recruiting, Sponsor: Fox Chase Cancer Center
Not yet recruiting --> Recruiting
- | Enrollment closed: Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer (clinicaltrials.gov) - Jul 27, 2018
P2, N=67, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | irinotecan / Generic mfg.
New P2 trial: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma (clinicaltrials.gov) - Jul 26, 2018
P2, N=25, Not yet recruiting, Sponsor: Khon Kaen University
- | New P1 trial, Metastases: Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 26, 2018
P1, N=30, Recruiting, Sponsor: University of Alabama at Birmingham
- | BNC-101 / Carina Biotech
Trial termination, Metastases: A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Jul 24, 2018
P1, N=22, Terminated, Sponsor: Bionomics Limited
Active, not recruiting --> Terminated; Monotherapy arm completed. Combination arm did not proceed (sponsor decision).
- | ompenaclid (RGX-202) / Inspirna, EMD Serono
New P1 trial, Combination therapy, Metastases: RGX-202-001: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 24, 2018
P1, N=60, Recruiting, Sponsor: Rgenix, Inc.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: PACHA-01: Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Jul 23, 2018
P2/3, N=220, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Combination arm did not proceed (sponsor decision). Trial completion date: May 2026 --> May 2028 | Trial primary completion date: May 2026 --> May 2028
- |||| Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Jul 23, 2018
P3, N=823, Active, not recruiting, Sponsor: Takeda
Trial completion date: May 2026 --> May 2028 | Trial primary completion date: May 2026 --> May 2028 Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Jul 23, 2018
P3, N=757, Active, not recruiting, Sponsor: Takeda
Trial completion date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020 Trial completion date: Jul 2021 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer (clinicaltrials.gov) - Jul 20, 2018
P1, N=52, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Jul 2021 --> May 2020 | Trial primary completion date: Feb 2020 --> May 2020 Trial completion date: Aug 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Sep 2021
- | Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci
Enrollment open, Trial initiation date, Combination therapy, Metastases: Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 20, 2018
P1/2, N=43, Recruiting, Sponsor: Aadi, LLC
Trial completion date: Aug 2020 --> Sep 2022 | Trial primary completion date: Aug 2020 --> Sep 2021 Not yet recruiting --> Recruiting | Initiation date: Apr 2018 --> Jul 2018
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, PharmaEngine, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal: Clinical Management: Metastatic Disease. (Pubmed Central) - Jul 19, 2018
More patients are also now able to be sequenced through 2 or more lines of treatment, with newer regimens such as nanoliposomal irinotecan plus infusional 5-fluorouracil and leucovorin receiving US Food and Drug Administration approval specifically for use in this second-line setting...In contrast, molecular predictors of efficacy and toxicity have not yet been validated in this disease context. Areas of novel therapeutic development include targeting the stromal microenvironment, exploring combinations of immunotherapeutic agents, and identifying molecular subsets of metastatic pancreatic cancer that may uniquely susceptible to specific strategies, such as hampering DNA damage repair.
- | Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jul 19, 2018
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Areas of novel therapeutic development include targeting the stromal microenvironment, exploring combinations of immunotherapeutic agents, and identifying molecular subsets of metastatic pancreatic cancer that may uniquely susceptible to specific strategies, such as hampering DNA damage repair. Trial primary completion date: Jun 2018 --> Dec 2018
- | Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer (clinicaltrials.gov) - Jul 19, 2018
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jun 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Dec 2018 --> Jul 2018
- | Enrollment closed, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: OncoSil Medical Limited
Recruiting --> Active, not recruiting | Trial completion date: Jan 2019 --> Jul 2019 | Trial primary completion date: Dec 2018 --> Jul 2018 Recruiting --> Active, not recruiting
- | Trial primary completion date, Combination therapy, Metastases: Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer (clinicaltrials.gov) - Jul 18, 2018
P2, N=30, Active, not recruiting, Sponsor: Bruckner Oncology
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2018 --> Aug 2018
- | conatumumab (AMG 655) / Amgen
Trial completion date, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Jul 18, 2018
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial primary completion date: Apr 2018 --> Aug 2018 Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Jan 2019
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Metastases: Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jul 18, 2018
P2, N=46, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Jan 2019 Not yet recruiting --> Recruiting
- | Trial completion, Surgery: Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer (clinicaltrials.gov) - Jul 17, 2018
P3, N=546, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion, Trial completion date, Trial primary completion date: AALL0631: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 17, 2018
P3, N=218, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: Locally Advanced or Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jul 15, 2018
P2, N=88, Enrolling by invitation, Sponsor: National Health Research Institutes, Taiwan
- || Sotyktu (deucravacitinib) / BMS
New P1 trial: A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (clinicaltrials.gov) - Jul 15, 2018
P1, N=30, Completed, Sponsor: Bristol-Myers Squibb
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Metastases: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (clinicaltrials.gov) - Jul 13, 2018
P2/3, N=252, Recruiting, Sponsor: Centre Georges Francois Leclerc
Active, not recruiting --> Completed | Trial completion date: Sep 2018 --> Dec 2017 | Trial primary completion date: Sep 2018 --> Sep 2017 Trial completion date: Feb 2022 --> Mar 2019
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, Combination therapy: A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors (clinicaltrials.gov) - Jul 13, 2018
P1, N=430, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Feb 2022 --> Mar 2019 Trial completion date: May 2019 --> Jan 2021
- | veliparib (ABT-888) / AbbVie, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change, Metastases: NRG-GI002: Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jul 13, 2018
P2, N=348, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2019 --> Jan 2021 N=174 --> 348
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Enrollment open: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 13, 2018
P2, N=78, Recruiting, Sponsor: Darren Carpizo, MD
N=174 --> 348 Not yet recruiting --> Recruiting
- |||| Vectibix (panitumumab) / Amgen
New P2 trial: OPTIPRIME: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (clinicaltrials.gov) - Jul 11, 2018
P2, N=118, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
- | thioguanine / Generic mfg.
Trial completion: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 11, 2018
P3, N=5377, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly
Trial primary completion date: PARECEC: Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis (clinicaltrials.gov) - Jul 11, 2018
P2/3, N=154, Recruiting, Sponsor: Beijing Cancer Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Sep 2018
- | EndoTAG-1 (paclitaxel liposomal) / Sinphar Pharma
Enrollment open, Metastases: EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (clinicaltrials.gov) - Jul 10, 2018
P3, N=214, Recruiting, Sponsor: SynCore Biotechnology Co., Ltd.
Trial primary completion date: Dec 2017 --> Sep 2018 Not yet recruiting --> Recruiting
- | Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial (clinicaltrials.gov) - Jul 10, 2018
P2, N=125, Recruiting, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Aug 2024 | Initiation date: Nov 2017 --> Jun 2018 | Trial primary completion date: Jul 2021 --> Aug 2022
- | leucovorin calcium / Generic mfg.
Phase classification: Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder (clinicaltrials.gov) - Jul 9, 2018
P2, N=162, Not yet recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Aug 2024 | Initiation date: Nov 2017 --> Jun 2018 | Trial primary completion date: Jul 2021 --> Aug 2022 Phase classification: P3 --> P2
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: ESOPEC: Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus (clinicaltrials.gov) - Jul 6, 2018
P3, N=438, Recruiting, Sponsor: University Hospital Freiburg
Phase classification: P3 --> P2 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jan 2022 --> Jun 2023
- | Imlygic (talimogene laherparepvec) / Amgen
Enrollment open, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Jul 6, 2018
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jan 2022 --> Jun 2023 Suspended --> Recruiting
- | thioguanine / Generic mfg.
Trial primary completion date: AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov) - Jul 5, 2018
P3, N=9483, Active, not recruiting, Sponsor: Children's Oncology Group
Suspended --> Recruiting Trial primary completion date: Mar 2020 --> Mar 2019
- || Xpovio (selinexor) / Karyopharm
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jul 5, 2018
P1, N=588, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2020 --> Mar 2019 Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: VITALITY: Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 5, 2018
P3, N=428, Recruiting, Sponsor: Sun Yat-sen University
Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2019 --> Dec 2019 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019
- |||| pimurutamab (HLX07) / Fosun Pharma
New P1/2 trial, Metastases: HLX07Ib/II: The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (clinicaltrials.gov) - Jul 5, 2018
P1/2, N=90, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- || ipatasertib (RG7440) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2018
P1, N=123, Active, not recruiting, Sponsor: Genentech, Inc.
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
- ||||||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Trial completion date, Combination therapy, Metastases: TAILOR: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (clinicaltrials.gov) - Jul 3, 2018
P3, N=553, Completed, Sponsor: Merck KGaA
Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018
- || Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov) - Jul 3, 2018
P2, N=40, Recruiting, Sponsor: University of Kansas Medical Center
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 Not yet recruiting --> Recruiting
- || navicixizumab (OMP-305B83) / Feng Biosci
Enrollment change, Metastases: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 29, 2018
P1b, N=30, Recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting N=60 --> 30
- | Tecentriq (atezolizumab) / Roche
Trial initiation date, Combination therapy: DANTE: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (clinicaltrials.gov) - Jun 29, 2018
P2, N=295, Not yet recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
N=60 --> 30 Initiation date: Feb 2018 --> Jul 2018
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jun 28, 2018
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Initiation date: Feb 2018 --> Jul 2018 Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Jan 2019
- | Avastin (bevacizumab) / Roche
Trial completion, Enrollment change: APPROACH: Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets (clinicaltrials.gov) - Jun 27, 2018
P2, N=79, Completed, Sponsor: Yonsei University
Trial completion date: Jul 2018 --> Jan 2019 | Trial primary completion date: Jul 2018 --> Jan 2019 Active, not recruiting --> Completed | N=218 --> 79
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment change: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 26, 2018
P3, N=509, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=218 --> 79 N=360 --> 509
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Jun 26, 2018
P2, N=30, Active, not recruiting, Sponsor: Safi Shahda, M.D.
N=360 --> 509 Trial completion date: Apr 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Dec 2019
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 26, 2018
P2, N=130, Active, not recruiting, Sponsor: Peking University